# US 2001/0026798 A1 · Methods of enhancing activity of vaccines and vaccine compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0026798 A1
- Document ID: US20010026798A1
- Status: Published application
- Kind: A1
- Application number: 09/797,760
- Filed: 2001-03-02
- Published: 2001-10-04
- Earliest claimed: 2000-03-02
- Assignees: MedImmune, LLC
- Inventors: Scott Koenig
- Web page: https://patentgrep.com/patent/US20010026798A1

## CPC

- C07K 16/11: Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 39/40: bacterial
- A61K 39/42: viral
- A61P 31/04: Antibacterial agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed are methods for vaccine priming, using co-treatment, at a temporally similar or at a previous time, with a priming antibody capable of priming, or enhancing, or potentiating the effects of a vaccine, or vaccine composition. Also disclosed are methods of using this process to prevent or treat disease.

## Claims

### Claim 1

A process for priming the immunogenic activity of a vaccine, or vaccine composition, comprising:
(a) administering to an animal in need thereof an effective amount of an antibody specific for one or more of the antigenic determinants characteristic of said vaccine, or vaccine composition;
(b) administering to said animal an effective amount of the vaccine, or vaccine composition, of step (a).

### Claim 2 (depends on 1)

The process of claim 1 wherein step (a) is carried out at least 24 hours before step (b).

### Claim 3 (depends on 1)

The process of claim 1 wherein step (a) is carried out at least 48 hours before step (b).

### Claim 4 (depends on 1)

The process of claim 1 wherein step (a) is carried out at least 72 hours before step (b).

### Claim 5 (depends on 1)

The process of claim 1 wherein step (a) is carried out at least 1 week before step (b).

### Claim 6 (depends on 1)

The process of claim 1 wherein the antibody is specific for more than one antigenic determinant present in the vaccine, or vaccine composition.

### Claim 7 (depends on 1)

The process of claim 1 wherein the vaccine, or vaccine composition, comprises at least one antigenic determinant for which the antibody of step (a) is not specific.

### Claim 8 (depends on 1)

The process of claim 1 wherein the vaccine, or vaccine composition, is useful in vaccinating against a microorganism.

### Claim 9 (depends on 8)

The process of claim 8 wherein the microorganism is a bacterium.

### Claim 10 (depends on 8)

The process of claim 8 wherein the microorganism is a virus.

### Claim 11 (depends on 10)

The process of claim 10 wherein the virus is respiratory syncytial virus (RSV).

### Claim 12 (depends on 11)

The process of claim 11 wherein the antibody is an anti-RSV antibody having specificity for the F antigen of RSV.

### Claim 13 (depends on 1)

The process of claim 1 wherein the effective amount of antibody is in the range of 5 to 20 mg/kg of body weight.

### Claim 14 (depends on 1)

The process of claim 1 wherein the effective amount of antibody is in the range of 10 to 20 mg/kg body weight.

### Claim 15 (depends on 12)

The process of claim 12 wherein the effective amount of antibody is about 15 mg/kg.

### Claim 16 (depends on 1)

The process of claim 1 wherein the affective amount of vaccine, or vaccine composition, is such as to result in introduction of at least about 5 μg per kg of body weight to about 1 gram per kg body weight.

### Claim 17 (depends on 1)

The process of claim 1 wherein the affective amount of vaccine, or vaccine composition, is such as to result in introduction of at least about 100 μg per kg of body weight to about 1 gram per kg body weight.

### Claim 18 (depends on 1)

The process of claim 1 wherein the affective amount of vaccine, or vaccine composition, is such as to result in introduction of at least about 1 mg per kg of body weight to about 1 gram per kg body weight.

### Claim 19 (depends on 1)

The process of claim 1 wherein the affective amount of vaccine, or vaccine composition, is such as to result in introduction of at least about 10 mg per kg of body weight to about 1 gram per kg body weight.

### Claim 20 (depends on 1)

The process of claim 1 wherein the vaccine, or vaccine composition, shows little or no immunogenic activity without priming step (a).

### Claim 21 (depends on 10)

The process of claim 10 wherein said virus is selected from the group consisting of parainfluenza virus (PIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), influenza A virus, and influenza B virus, including genetically engineered forms of said viruses.

### Claim 22 (depends on 1)

A process for treating or preventing a disease by carrying out the steps of claim 1 on an animal at risk of said disease, or afflicted with said disease.

### Claim 23 (depends on 23)

The process of claim 23 wherein said animal is a human being.

### Claim 24 (depends on 23)

The process of claim 23 wherein said disease is cancer.

### Claim 25 (depends on 1)

A process for treating a condition caused by exposure to a toxin comprising treating a patient in need thereof with the process of claim 1.
